Tharimmune Announces Intent to Acquire Intract Pharma
Company Announcements

Tharimmune Announces Intent to Acquire Intract Pharma

Don't Miss out on Research Tools:

Tharimmune ( (THAR) ) has shared an announcement.

Tharimmune, Inc. has announced its intent to acquire Intract Pharma Limited, aiming to purchase all outstanding shares of Intract in a stock-for-stock transaction. This significant move, intended to expand Tharimmune’s market presence, should be considered alongside the company’s other public disclosures. However, investors are cautioned to not place undue reliance on forward-looking statements provided in the presentation material.

Find detailed analytics on THAR stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyTharimmune presents clinical data on TH104 for chronic pruritus
TheFlyTharimmune granted patent for delivery of molecularly targeted therapeutics
TheFlyTharimmune receives regulatory feedback from EMA for TH104 program
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App